Fortress Biotech Inc Quick Ratio (FBIO) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
FBIO's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth
In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 1.81 below Fortress Biotech Inc average.
Within Major Pharmaceutical Preparations industry 295 other companies have achieved higher Quick Ratio than Fortress Biotech Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1104 to 1475.
Fortress Biotech Makes Strategic Move with $8 Million Registered Direct Offering to Support Growth and InnovationMIAMI, Sept. 20, 2024 Fortress Biotech, Inc. (Nasdaq: FBIO), a dynamic biopharmaceutical firm dedicated to acquiring and advancing innovative assets, has announced a significant financial maneuver designed to bolster its growth and enhance shareholder value. On September 19, Fortress Biotech entered into securities purchase agreements with institutional investors focused on healthcare, issuing and selling 3,939,394 shares of common stock at a purchase price of $1.65 per share. This action is part of a registered direct offering that will raise approximately $8 million for the company.In a concurrent private placement, Fortress Biotech committed to issuing warrants to the same group of investors, allowing them to purchase an equivalent number of shares at an exercise price of $1.84 per share. These warrants will become exercisable six months from their date of issuance and will remain valid for a period of five and one-half years. This dual offering strategy positions Fortress Biotech to strategically align its financial resources with its growth initiatives.
Fortress Biotech Inc. and Cyprium Therapeutics have recently announced a significant milestone in the development of a potential treatment for Menkes disease. Encouraging preclinical studies have shown the potential to combine AAV-ATP7A gene therapy with CUTX-101, which could potentially become the first FDA-approved treatment for this rare genetic disorder. Menkes disease, also known as Menkes syndrome, is a rare genetic disorder that affects copper metabolism in the body. This leads to a copper deficiency, which can cause severe developmental delays and neurological problems. It primarily affects males and is estimated to occur in about 1 in every 100,000 live births.
Fortress Biotech, an innovative biopharmaceutical company dedicated to acquiring, developing, and commercializing promising therapeutic products and candidates, recently unveiled a groundbreaking definitive agreement for an issuance and sale of its common stock and accompanying warrants. The move is aimed at further strengthening its product pipeline, enhancing research and development efforts, and advancing their position in the highly competitive biotech industry. Under the agreement, Fortress Biotech will offer a total of 3,303,305 shares of its common stock along with warrants to purchase the same number of shares, both at a combined offering price of $3.33 per share. By adhering to the Nasdaq rules, the company is aptly aligning its market strategy with industry best practices. The accompanying warrants have an exercise price of $3.21 per share, ensuring immediate exercisability for investors and providing additional capital infusion for future growth initiatives. These warrants also possess a term of five years, further solidifying Fortress Biotech s long-term vision and commitment to success.
On the trailing twelve months basis FBIO Cash & cash equivalent more than doubled by 164.26 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Fortress Biotech Inc 's Quick Ratio to 1.96, Quick Ratio remained below FBIO average. Quick Ratio is the average cumulative value over the last four quarters.
Among companies operating within Major Pharmaceutical Preparations industry 430 other companies have achieved higher Quick Ratio than Fortress Biotech Inc . While Quick Ratio overall ranking has improved so far to 3791, from total ranking during the twelve months ending first quarter 2026 at 3874.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
